PoreWise One finding · Human trial · 2026
Study title
Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway
- Kind of evidence
- Human trial 2026 · 50 people · women with melasma · PMID 42059427
- Measured outcome
- Skin effect
- Year
- 2026
- Who was studied
- 50 women with melasma
- Sample size
- 50
- Measured outcome
- In a randomized study of 50 women with melasma, topical 3% tranexamic acid serum plus moisturizer reduced periorbital wrinkle grading significantly more than moisturizer alone at weeks 4, 8 and 12, with the benefit persisting after treatment stopped.
- Certainty
- Moderate
- Who was measured
- Women with melasma applying 3% topical tranexamic acid serum plus moisturizer (vs moisturizer alone) for 8 weeks, follow-up to week 12.
- Study limits
- The population is melasma patients.
Where it comes from
- Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway
Published by Annals of Medicine (Lin Y, Wang Y, Wang W, et al.) · Last checked 2026-10-29
Ingredients it was measured on
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectRandomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma
In a randomized trial of 50 female melasma patients, a topical 5% tranexamic acid cream applied twice daily for 12 weeks reduced the Melasma Area and Severity Index by 50.88% (p=0.001).
Human trial · 2025 · 50 people · female melasma patients · Female melasma patients applying a 5% topical tranexamic acid cream twice daily for 12 weeks (compared with an oral tranexamic acid arm). · Small sample (50) and a single-centre study; the trial compared topical against oral tranexamic acid.
- Skin effectEfficacy and Tolerability of a Topical Pigment-Correcting Serum in Melasma and Postinflammatory Hyperpigmentation
In 30 women with melasma or post-inflammatory hyperpigmentation, a serum combining lotus sprout extract, tranexamic acid and niacinamide reduced skin tone unevenness by 38% and 33% respectively over 16 weeks (P < 0.008).
Human trial · 2026 · 30 people · women (15 melasma, 15 PIH), 70% Fitzpatrick IV-VI · Women with melasma or PIH, 70% with Fitzpatrick skin types IV-VI, applying the serum twice daily for 16 weeks. · 30 participants; "skin tone unevenness" is a sponsor-defined endpoint.
- Skin effectEfficacy of a New Topical Nano-hyaluronic Acid in Humans
Eight weeks of a low-molecular-weight "nano" hyaluronic acid lotion, serum and cream reduced measured periorbital wrinkle depth by up to 40% and raised corneometer hydration by up to 96%.
Human trial · 2014 · 33 people · Women with a mean age of 45.2 years · A three-step regimen (lotion, serum, cream) built on a low-molecular-weight hyaluronic acid, used for eight weeks on women with a mean age of 45.2. · The percentages are within-group changes. 33 participants in one centre, and the material is described as "nano" hyaluronic acid.
- Skin effectEfficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment
Periocular wrinkle depth improved against vehicle with the 50 kDa and 130 kDa hyaluronic acid creams; after 60 days the 300, 800 and 2000 kDa creams matched vehicle on measured roughness.
Human trial · 2011 · 76 people · Women aged 30-60 with periocular wrinkles · Replica-based roughness measurement (mean roughness Ra, maximum roughness Rz) of periocular wrinkles, with 0.1% creams applied twice daily for 60 days. · Wrinkle depth was an instrumental secondary measure on women who already had periocular lines. The trial stopped at 60 days. The five creams differed in molecular weight, shared a base formula.
- Skin effectImprovement of naturally aged skin with vitamin A (retinol)
A 0.4% retinol lotion applied to the arm up to three times a week for 24 weeks reduced fine wrinkling significantly more than its vehicle in elderly subjects: score change −1.64 (95% CI −2.06 to −1.22) against −0.08 (−0.17 to 0.01) on a 0–9 severity scale.
Human trial · 2007 · 36 people · Elderly adults, mean age 87 · Elderly adults, arms. · Thirty-six participants in two senior-care facilities, average age 87, an unusual population for cosmetic use. The glycosaminoglycan and procollagen measurements that suggest a mechanism came from subgroups of six and four participants, far too small to stand on their own.